Hologic, Inc. reported fiscal first‑quarter 2026 revenue of $1.0478 billion, a 2.5% year‑over‑year increase from $1.0218 billion in the same period last year, but the figure fell short of the consensus estimate of roughly $1.09 billion. Non‑GAAP diluted earnings per share were $1.04, missing the consensus of $1.11, while GAAP diluted EPS of $0.79 also fell below the prior year’s $0.87. The miss on both revenue and earnings was driven primarily by a 1.3% decline in the diagnostics segment, which was heavily impacted by the continued erosion of COVID‑19 related sales.
Diagnostics revenue dropped to $464.4 million, a 1.3% year‑over‑year decline, reflecting the loss of high‑volume COVID‑19 testing contracts. Breast health revenue rose 1.8% to $375.9 million, supported by strong sales of Endomagnetics products following the company’s acquisition of the firm. GYN surgical revenue increased 8.7% to $180.8 million, driven by the integration of Gynesonics and organic growth of 3.2% in surgical procedures. Interventional breast solutions, a sub‑segment of breast health, grew 9.6% year‑over‑year, a more modest increase than the 31.8% figure originally reported. Skeletal health revenue surged 69% to $X million, underscoring the company’s expanding footprint in orthopedics.
Gross margin contracted to 56.0% from 56.8% in Q1 2025, a decline largely attributable to a $15.3 million increase in tariff expenses that eroded the cost base. Operating margin held steady at 22.6%, up 0.1 percentage point from the prior year, as cost‑control initiatives offset the margin pressure from tariffs. Non‑GAAP operating margin fell 0.4 percentage points to 29.0%, reflecting the impact of the tariff expense on the company’s adjusted profitability profile.
Hologic is not providing any forward guidance for fiscal 2026, citing the pending acquisition by Blackstone and TPG. The company also declined to host a conference call to discuss the results, a decision that limits the amount of management commentary available to investors. The lack of guidance signals uncertainty about the company’s near‑term outlook amid the transition to new ownership.
Market reaction to the earnings was negative, with investors focusing on the revenue and EPS misses. The diagnostics decline, combined with the company’s decision to forego a conference call, contributed to a muted response from the market, reflecting concerns about the company’s ability to sustain growth in the post‑COVID era.
Management’s statement noted that the company’s agreement to be acquired by Blackstone and TPG precludes the issuance of guidance for the year and that the company will not host a conference call to discuss the results. The statement underscored the company’s focus on executing its integration plans and maintaining operational discipline during the transition.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.